Growth Metrics

Sarepta Therapeutics (SRPT) Gross Profit (2017 - 2025)

Sarepta Therapeutics (SRPT) has 8 years of Gross Profit data on record, last reported at -$1.2 billion in Q4 2024.

  • For Q4 2024, Gross Profit fell 378.54% year-over-year to -$1.2 billion; the TTM value through Dec 2024 reached $512.6 million, down 38.11%, while the annual FY2024 figure was -$205.1 million, 118.76% down from the prior year.
  • Gross Profit reached -$1.2 billion in Q4 2024 per SRPT's latest filing, down from $1.0 billion in the prior quarter.
  • Across five years, Gross Profit topped out at $1.0 billion in Q3 2024 and bottomed at -$1.2 billion in Q4 2024.
  • Average Gross Profit over 5 years is $136.1 million, with a median of $141.5 million recorded in 2021.
  • The widest YoY moves for Gross Profit: up 6993.88% in 2024, down 378.54% in 2024.
  • A 5-year view of Gross Profit shows it stood at $38.5 million in 2020, then skyrocketed by 108.39% to $80.2 million in 2021, then soared by 72.48% to $138.4 million in 2022, then skyrocketed by 203.04% to $419.4 million in 2023, then crashed by 378.54% to -$1.2 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Gross Profit were -$1.2 billion in Q4 2024, $1.0 billion in Q3 2024, and $316.0 million in Q2 2024.